induced pluripotent stem cell-derived hepatocyte-like cells (Salk Institute)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameinduced pluripotent stem cell-derived hepatocyte-like cells (Salk Institute)
Drug Alias Namehepatocyte-like cells (Salk Institute)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCoagulation factor IX modulators
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSalk Institute for Biological Studies
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSalk Institute for Biological Studies
Active IndicationsN/A
Inactive IndicationsHemophilia B

Other Information

ATC CodeN/A
Related LinksN/A